Tags

Type your tag names separated by a space and hit enter

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Expert Rev Cardiovasc Ther. 2009 May; 7(5):459-64.ER

Abstract

Hypertension control is critical to prevent stroke. With several clinical trials conducted over the last decade, it seems that the use of an angiotensin-modulating antihypertensive agent conveys benefits beyond blood pressure reduction. Currently, there is evidence supporting the use of either an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor in the primary-prevention context. However, in the secondary prevention of stroke, the choice of agent is less clear. There is evidence that intensive blood pressure reduction with a combination of an angiotensin-converting enzyme inhibitor and a diuretic can reduce stroke recurrence, but do angiotensin receptor blockers have the same ability? The Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES) trial endeavors to answer this question and strives to demonstrate the benefit of angiotensin receptor blockers in the secondary prevention of stroke.

Authors+Show Affiliations

Calgary Stroke Program, University of Calgary, Foothills Medical Centre, Room 1162, 1403 29th Street NW, Calgary, AB, T2N 2T9, Canada.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19419253

Citation

Dowlatshahi, Dar, and Michael D. Hill. "Angiotensin Receptor Blockers and Secondary Stroke Prevention: the MOSES Study." Expert Review of Cardiovascular Therapy, vol. 7, no. 5, 2009, pp. 459-64.
Dowlatshahi D, Hill MD. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study. Expert Rev Cardiovasc Ther. 2009;7(5):459-64.
Dowlatshahi, D., & Hill, M. D. (2009). Angiotensin receptor blockers and secondary stroke prevention: the MOSES study. Expert Review of Cardiovascular Therapy, 7(5), 459-64. https://doi.org/10.1586/erc.09.3
Dowlatshahi D, Hill MD. Angiotensin Receptor Blockers and Secondary Stroke Prevention: the MOSES Study. Expert Rev Cardiovasc Ther. 2009;7(5):459-64. PubMed PMID: 19419253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Angiotensin receptor blockers and secondary stroke prevention: the MOSES study. AU - Dowlatshahi,Dar, AU - Hill,Michael D, PY - 2009/5/8/entrez PY - 2009/5/8/pubmed PY - 2009/8/25/medline SP - 459 EP - 64 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 7 IS - 5 N2 - Hypertension control is critical to prevent stroke. With several clinical trials conducted over the last decade, it seems that the use of an angiotensin-modulating antihypertensive agent conveys benefits beyond blood pressure reduction. Currently, there is evidence supporting the use of either an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor in the primary-prevention context. However, in the secondary prevention of stroke, the choice of agent is less clear. There is evidence that intensive blood pressure reduction with a combination of an angiotensin-converting enzyme inhibitor and a diuretic can reduce stroke recurrence, but do angiotensin receptor blockers have the same ability? The Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES) trial endeavors to answer this question and strives to demonstrate the benefit of angiotensin receptor blockers in the secondary prevention of stroke. SN - 1744-8344 UR - https://www.unboundmedicine.com/medline/citation/19419253/Angiotensin_receptor_blockers_and_secondary_stroke_prevention:_the_MOSES_study_ L2 - http://www.tandfonline.com/doi/full/10.1586/erc.09.3 DB - PRIME DP - Unbound Medicine ER -